XML 42 R28.htm IDEA: XBRL DOCUMENT

Transition Period Comparative Data (Unaudited)

6 Months Ended

Dec. 31, 2020

TRANSITION PERIOD COMPARATIVE DATA (UNAUDITED)


(in millions)	Six-month Period Ended
Consolidated Statement of Operations Data:	December 31, 2019
Molecular diagnostic testing	$	353.1
Pharmaceutical and clinical services	28.3
Total revenue	381.4
Costs and expenses:
Cost of molecular diagnostic testing	82.2
Cost of pharmaceutical and clinical services	17.1
Research and development expense	40.1
Change in the fair value of contingent consideration	0.6
Selling, general and administrative expense	269.8
Goodwill and intangible asset impairment charges	1.3
Total costs and expenses	411.1
Operating loss	(29.7)
Other income (expense):
Interest income	1.7
Interest expense	(5.4)
Other	(0.3)
Total other expense	(4.0)
Loss before income taxes	(33.7)
Income tax benefit	(4.8)
Net loss	(28.9)
Net loss attributable to non-controlling interest	—
Net loss attributable to Myriad Genetics Inc. stockholders	$	(28.9)
Loss per share:
Basic	$	(0.39)
Diluted	$	(0.39)
Weighted average shares outstanding:
Basic	74.1
Diluted	74.1